Advertisement

Topics

Companies Related to "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment" [Most Relevant Company Matches] - Page: 3 RSS

00:46 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment" found in our extensive corporate database of over 50,000 company records.

Showing "Efficacy Safety Empagliflozin 10773 Patients With Type Diabetes" Companies 51–75 of 5,800+

Relevant

VeraLight, Inc.

VeraLight, Inc., established in 2004 as an independent spinout of InLight Solutions, is applying its proprietary Spectroscopic Advanced Glycation Endproduct (SAGE) detection technology to develop the SCOUT DS system -- intended to be the first non-invasive diabetes screening system that provides healthcare professionals with an accurate and convenient method for detecting type 2 diabetes and p...


Juvenile Diabetes Research Foundation

The Sansum Diabetes Research Institute is a non-profit research center devoted to the prevention, treatment and cure of diabetes through research and education. It is best known for its work on diabetes and pregnancy and its expertise in new diabetes technology.

Medality Medical LLC

Medality Medical LLC, a privately funded (including an NIH grant) medical technology company, is focused on reversing type 2 diabetes and associated obesity. Its patented proprietary technology enables the gentle and selective extraction of excess mesenteric visceral fat, which has been associated with insulin resistance, a precursor to type 2 diabetes. In...


Prosidion Ltd

(OSI) Prosidion is the diabetes and obesity business group within OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. (OSI) Prosidion's lead compound PSN9301 is a Dipeptidyl Peptidase IV (DP-IV) inhibitor currently in Phase II clinical trials. PSN357, a glycogen phosphorylase inhibitor, is undergoing Ph...

Cortendo AB

Cortendo AB is a biopharmaceutical company headquartered in Göteborg, Sweden. Its stock is publicly traded on the NOTC-A-list (OTC) in Norway. Cortendo is a pioneer in the field of cortisol inhibition and has completed early clinical trials in patients with Type 2 diabetes. The lead drug candidate NormoCort, the 2S, 4R-enantiomer of ketoconazole, has be...

MedAutonomic

MedAutonomic is a privately held medtech company dedicated to developing a bioelectric medicine to treat patients with functional diseases of the metabolic syndrome such as type-2 diabetes, hypertension and gastroesophageal reflux disease (GERD). MedAutonomic’s approach is to offer a nonsurgical alternative treatment of functional diseases with a lowe...

Onlife Health, Inc.

Simplex Healthcare is based in Franklin, Tennessee and provides home delivery of medical supplies to help patients with diabetes. Simplex secured $50 million in venture capital from New Enterprise Associates and acquired Diabetes Care Club in September 2007. Prior to the acquisition, DCC employed 35 associates and had a patient base of 20,000 patients with...

BioCell Technology

BioCell Collagen is a clinically tested dietary ingredient that promotes active joints, youthful-looking skin, and healthy connective tissues. BioCell Collagen contains a patented composition of naturally occurring hydrolyzed collagen type II (60-70%), chondroitin sulfate (20%), and hyaluronic acid (10%) in a highly absorbable matrix form that has been the...

Alzheon Inc.

Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ-801, is a first-in-class, oral inhibitor of amyloid aggregation and neurotoxicity - hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodru...

Harbor BioSciences, Inc.

Harbor BioSciences is a development-stage company with two product candidates in clinical trials: Apoptone (HE3235), in the cohort expansion portion of a Phase I/IIa trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone and Triolex represent the lead candidates from Harbor BioSciences' small molecule platform bas...

Diabetes Care Club

Diabetes Care Club, a Simplex brand, has grown to become the third largest mail-order supplier of diabetic testing supplies for seniors. The company provides home delivery of medical supplies for patients with diabetes and a social network that offers help, support and information for people living with the disease. For additional information, visit www.Di...

Advanced Sterilization Products

Advanced Sterilization Products (ASP) division of Ethicon, Inc., is a leading developer of innovative instrument sterilization, high-level disinfection, and cleaning technologies. The company is dedicated to protecting patients, healthcare workers, and the environment with products that focus as much on safety as they do on efficacy and cost-effectiveness. Utilizing advanced instrument processing ...

TolerRx, Inc.

We are a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat patients with immunological diseases. TolerRx has a development pipeline which includes two humanized antibodies that are in clinical trials for new-onset type 1 diabetes, psoriasis, and cutaneous lupus erythematosus. We also have ongoing research and development programs foc...

MacuSight, Inc.

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part...

Opexa Therapeutics

Opexa Therapeutics is a commercialization driven biotechnology cellular therapy company that develops autologous personalized cell therapies for the treatment of various diseases. The Company is focused on its proprietary stem cell and T-cell technologies for the autologous use of peripheral blood derived adult stem cells in regenerative medicine as well as T cells for the treatment of autoimmune ...

Santarus, Inc. and Depomed, Inc.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylat...

Santarus, Inc. & Depomed, Inc.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company’s current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine me...

CureDM, Inc.

CureDM, Inc., is a privately held, biopharmaceutical company focused on the discovery and development of new therapies that prevent, ameliorate, or reverse diseases of metabolism. CureDM is located in the Lankenau Institute for Medical Research (LIMR) at the Lankenau Hospital campus in Wynnewood, PA. CureDM has completed nearly all preclinical studies for ...

Hollis-Eden Pharmaceuticals, Inc.

Hollis-Eden Pharmaceuticals is a development-stage company with two product candidates in clinical trials: Apoptone® (HE3235), in the dose-escalation portion of a Phase I/II trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone® and Triolex® represent the lead candidates from Hollis-Eden's small molecule pla...

TheraCoat

TheraCoat is a specialty pharmaceutical company founded in 2004 by uro-oncologists and biomaterial specialists. TheraCoat’s Board of Directors and Scientific Advisory Board feature renowned scientific experts in the fields of urology, pharma top executives and experienced business veterans; among them Prof. Belldegrun and Mr. Hurvitz, both TEVA Board ...

Bayer HealthCare, Diabetes Care

Bayer Diabetes Care, a worldwide leader in diabetes, supports customers in 100 countries. Since 1941, Bayer has led the way in diabetes care product innovation with: reagent tablets, the first portable blood glucose meter and test strips, the measurement of A1C (glycated hemoglobin) with the A1CNow+ monitor, and the first suite of blood glucose monitors with No Coding(TM) technology (CONTOUR and ...

Metabolex, Inc.

Metabolex is dedicated to the discovery and development of novel therapeutics that will transform the treatment of diabetes and related metabolic disorders. We have created the largest database of genes involved in the disease and have used the information to generate a pipeline of potentially ground-breaking diabetes treatments.Our lead drug candidate, metaglidasen, is a novel, oral insulin sensi...

VivoScript, Inc.

Based in Orange County, California, VivoScript is an emerging biotech company established to commercialize a disruptive innovation in regenerative medicine. The new technology platform is named In Vivo Cell Reprogramming, or IVR. Using a combination of protein drugs, we can convert or reprogram one type of cells (substrate cells) to another type of cells (...

Quintiles Scotland

Safety PharmacologyQuintiles has safety pharmacology services to identify the potential adverse pharmacological effects of new chemical entities prior to first administration to man. Regulatory Safety Pharmacology packages Haemodynamics/ECG studies Cardiac action potential in vitro QT prolongationIon channels (e.g. HERG) Discovery SupportQuintiles pharmacologists can provide support in defining th...

Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACC...


More From BioPortfolio on "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks